SWOG clinical trial number
CTSU/A081801
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Open
Phase
Abbreviated Title
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Status Notes
Effective March 15, 2022, A081801 will be re-activated to accrual.
Activated
06/23/2020
Research committees
Lung Cancer
Treatment
Cisplatin
Carboplatin
Gemcitabine hydrochloride
Radiation Therapy
Pemetrexed
MK-3475
Paclitaxel
Eligibility Criteria Expand/Collapse
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.
Publication Information Expand/Collapse
2021
PMid: PMID33878954 | PMC number: PMC8293026
Other Clinical Trials
SWOG Clinical Trial Number
S2302
PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
63%
Open
Phase
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open